News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Deals
Astellas Pharma Inc. Extends OSI Pharmaceuticals, Inc. Offer, Again
April 23, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- OSI Pharmaceuticals Inc, which has been fending off a hostile takeover bid by Japan's Astellas Pharma Inc, reported much lower first quarter profit on Thursday as results were hit by costs associated with the tender offer.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Astellas Pharma US, Inc.
MORE ON THIS TOPIC
Mergers & acquisitions
Merck, AstraZeneca Cancer Collaborator Gets Swallowed Up by Sino Biopharm
July 16, 2025
·
1 min read
·
Tristan Manalac
Cancer
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B
July 10, 2025
·
1 min read
·
Dan Samorodnitsky
Gene therapy
AstraZeneca Gains More Gene Therapy AAVs in JCR Deal Worth up to $825M
July 9, 2025
·
1 min read
·
Dan Samorodnitsky
M&A
Merck Makes Big Respiratory Play With $10B Acquisition of Verona
July 9, 2025
·
2 min read
·
Tristan Manalac